Basic Information
RNALocate ID: | RLID:01002271 |
RNA Symbol: | hsa-miR-424-5p |
Localization: | Nucleus |
RNA Information
RNA Name: | hsa-miR-424 |
RNA ID: | miRBase:MIMAT0001341 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 24918059 |
Tissue/Cell Line: | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) |
Method: | Microarray |
Description: | Data are collected from supplementary Table S2. MiRNA reads in the subcellular fractions. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002268 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01002269 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01002270 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:11002735 | Exosome | Serum | 18589210 |
RLID:11002736 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11002737 | Exosome | Brain tissue | 23382797 |
RLID:11002738 | Exosome | Plasma | 23663360 |
RLID:11002739 | Exosome | Serum | 25349172 |
RLID-D:11000137 | Exosome | Endothelial cells | |
RLID-D:11000448 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-424-5p | Splenic marginal zone lymphoma | MNDR-E-MI-48728 |
MNDR | hsa-miR-424-5p | Oral squamous cell carcinoma | MNDR-E-MI-48729 |
MNDR | hsa-miR-424-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-48730 |
MNDR | hsa-miR-424-5p | Ovarian clear cell carcinoma | MNDR-E-MI-48731 |
MNDR | hsa-miR-424-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-48732 |
MNDR | hsa-miR-424-5p | Lymphoma | MNDR-E-MI-48733 |
MNDR | hsa-miR-424-5p | Lymphoma non-hodgkin | MNDR-E-MI-48734 |
MNDR | hsa-miR-424-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-48735 |
MNDR | hsa-miR-424-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-48736 |
MNDR | hsa-miR-424-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-48737 |
MNDR | hsa-miR-424-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-48738 |
MNDR | hsa-miR-424-5p | Triple negative breast cancer | MNDR-E-MI-48739 |
MNDR | hsa-miR-424-5p | Breast cancer luminal | MNDR-E-MI-48740 |
MNDR | hsa-miR-424-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-48741 |
MNDR | hsa-miR-424-5p | Dermatomyositis | MNDR-E-MI-48742 |
MNDR | hsa-miR-424-5p | Prostate cancer | MNDR-E-MI-48743 |
MNDR | hsa-miR-424-5p | Chronic lymphocytic leukemia | MNDR-E-MI-48744 |
MNDR | hsa-miR-424-5p | Gastric cancer | MNDR-E-MI-48745 |
MNDR | hsa-miR-424-5p | Gastric lymphoma | MNDR-E-MI-48746 |
MNDR | hsa-miR-424-5p | Alzheimer disease | MNDR-E-MI-48747 |
MNDR | hsa-miR-424-5p | Intracranial aneurysm | MNDR-E-MI-48748 |
MNDR | hsa-miR-424-5p | Urinary bladder cancer | MNDR-E-MI-48749 |
MNDR | hsa-miR-424-5p | Dysautonomia familial | MNDR-E-MI-48750 |
MNDR | hsa-miR-424-5p | Head and neck cancer | MNDR-E-MI-48751 |
MNDR | hsa-miR-424-5p | Leukemia | MNDR-E-MI-48752 |
MNDR | hsa-miR-424-5p | Cardiovascular disease | MNDR-E-MI-48753 |
MNDR | hsa-miR-424-5p | Lung cancer | MNDR-E-MI-48754 |
MNDR | hsa-miR-424-5p | Down syndrome | MNDR-E-MI-48755 |
MNDR | hsa-miR-424-5p | Parkinson disease | MNDR-E-MI-48756 |
MNDR | hsa-miR-424-5p | Breast cancer | MNDR-E-MI-48757 |
MNDR | hsa-miR-424-5p | Neuroendocrine neoplasia | MNDR-E-MI-48758 |
MNDR | hsa-miR-424-5p | Pituitary neoplasms | MNDR-E-MI-48759 |
MNDR | hsa-miR-424-5p | Pancreatic cancer | MNDR-E-MI-48760 |
MNDR | hsa-miR-424-5p | Melanoma | MNDR-E-MI-48761 |
MNDR | hsa-miR-424-5p | Rectum adenocarcinoma | MNDR-E-MI-48762 |
MNDR | hsa-miR-424-5p | Nephroblastoma | MNDR-E-MI-48763 |
MNDR | hsa-miR-424-5p | Colon cancer | MNDR-E-MI-48764 |
MNDR | hsa-miR-424-5p | Colon adenocarcinoma | MNDR-E-MI-48765 |
MNDR | hsa-miR-424-5p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-48766 |
MNDR | hsa-miR-424-5p | Ovarian cancer | MNDR-E-MI-48767 |
MNDR | hsa-miR-424-5p | Prostate adenocarcinoma | MNDR-E-MI-48768 |
MNDR | hsa-miR-424-5p | Kidney cancer | MNDR-E-MI-48769 |
MNDR | hsa-miR-424-5p | Carcinoma ductal breast | MNDR-E-MI-48770 |
MNDR | hsa-miR-424-5p | Glioblastoma | MNDR-E-MI-48771 |
MNDR | hsa-miR-424-5p | Glioma | MNDR-E-MI-48772 |
MNDR | hsa-miR-424-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-48773 |
MNDR | hsa-miR-424-5p | Coronary artery disease | MNDR-E-MI-48774 |
MNDR | hsa-miR-424-5p | Meningioma | MNDR-E-MI-48775 |
MNDR | hsa-miR-424-5p | Gastric adenocarcinoma | MNDR-E-MI-48776 |
MNDR | hsa-miR-424-5p | Pituitary adenoma | MNDR-E-MI-48777 |
MNDR | hsa-miR-424-5p | Lung squamous cell carcinoma | MNDR-E-MI-48778 |
MNDR | hsa-miR-424-5p | Lung adenocarcinoma | MNDR-E-MI-48779 |
MNDR | hsa-miR-424-5p | Adrenocortical cancer | MNDR-E-MI-48780 |
MNDR | hsa-miR-424-5p | Thyroid carcinoma | MNDR-E-MI-48781 |
MNDR | hsa-miR-424-5p | Ovarian carcinoma | MNDR-E-MI-48782 |
MNDR | hsa-miR-424-5p | Pancreatic adenocarcinoma | MNDR-E-MI-48783 |
MNDR | hsa-miR-424-5p | Brain stem cancer | MNDR-E-MI-48784 |
MNDR | hsa-miR-424-5p | Cervical cancer | MNDR-E-MI-48785 |
MNDR | hsa-miR-424-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-48786 |
MNDR | hsa-miR-424-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-48787 |
MNDR | hsa-miR-424-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-48788 |
MNDR | hsa-miR-424-5p | Renal clear cell carcinoma | MNDR-E-MI-48789 |
MNDR | hsa-miR-424-5p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-48790 |
MNDR | hsa-miR-424-5p | Cholangiocarcinoma | MNDR-E-MI-48791 |
MNDR | hsa-miR-424-5p | Esophageal cancer | MNDR-E-MI-48792 |
MNDR | hsa-miR-424-5p | Oncocytoma | MNDR-E-MI-48793 |
MNDR | hsa-miR-424-5p | Synovial sarcoma | MNDR-E-MI-48794 |
MNDR | hsa-miR-424-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-48795 |
MNDR | hsa-miR-424-5p | Aortic valve disease | MNDR-E-MI-48796 |
MNDR | hsa-miR-424-5p | Breast invasive carcinoma | MNDR-E-MI-48797 |
MNDR | hsa-miR-424-5p | Hepatocellular carcinoma | MNDR-E-MI-48798 |
MNDR | hsa-miR-424-5p | B-cell lymphoma | MNDR-E-MI-48799 |
MNDR | hsa-miR-424-5p | Rheumatoid arthritis | MNDR-E-MI-48800 |
MNDR | hsa-miR-424-5p | T-cell leukemia | MNDR-E-MI-48801 |
MNDR | hsa-miR-424-5p | Retinoblastoma | MNDR-E-MI-48802 |
MNDR | hsa-miR-424-5p | Chronic myeloid leukemia | MNDR-E-MI-48803 |
MNDR | hsa-miR-424-5p | Burkitt lymphoma | MNDR-E-MI-48804 |
MNDR | hsa-miR-424-5p | Mouth neoplasms | MNDR-E-MI-48805 |
MNDR | hsa-miR-424-5p | Tonsil cancer | MNDR-E-MI-48806 |
MNDR | hsa-miR-424-5p | Psoriasis | MNDR-E-MI-48807 |
MNDR | hsa-miR-424-5p | Skin cutaneous melanoma | MNDR-E-MI-48808 |
MNDR | hsa-miR-424-5p | Skin melanoma | MNDR-E-MI-48809 |
MNDR | hsa-miR-424-5p | Acute myelocytic leukemia | MNDR-E-MI-48810 |
MNDR | hsa-miR-424-5p | Colorectal cancer | MNDR-E-MI-48811 |
MNDR | hsa-miR-424-5p | Nasopharynx carcinoma | MNDR-E-MI-48812 |
MNDR | hsa-miR-424-5p | Multiple myeloma | MNDR-E-MI-48813 |
MNDR | hsa-miR-424-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-48814 |
MNDR | hsa-miR-424-5p | Cardiomegaly | MNDR-E-MI-48815 |
MNDR | hsa-miR-424-5p | Nasopharyngeal cancer | MNDR-E-MI-48816 |
MNDR | hsa-miR-424-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-48817 |
MNDR | hsa-miR-424-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-48818 |
MNDR | hsa-miR-424-5p | Venous thromboembolism | MNDR-E-MI-48819 |
MNDR | hsa-miR-424-5p | Stroke lacunar | MNDR-E-MI-48820 |
MNDR | hsa-miR-424-5p | Breast cancer her3+ negative | MNDR-E-MI-48821 |
MNDR | hsa-miR-424-5p | High grade dysplastic nodule | MNDR-E-MI-48822 |
MNDR | hsa-miR-424-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-48823 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | AGO4 | Homo sapiens | RR00056009 |
TOP